{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T17:24:07Z","timestamp":1785777847128,"version":"3.56.0"},"reference-count":138,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000926","name":"Leukaemia Foundation Australian Capital Territory","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000926","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.blre.2021.100832","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T13:58:26Z","timestamp":1618927106000},"page":"100832","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Immunity reloaded: Deconstruction of the PD-1 axis in B cell lymphomas"],"prefix":"10.1016","volume":"50","author":[{"given":"Karolina","family":"Bednarska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Nath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Nicol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maher K.","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2021.100832_bb0005","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/70932","article-title":"B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2021.100832_bb0010","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2017-07-796342","article-title":"Immune evasion via PD-1\/PD-L1 on NK cells and monocyte\/macrophages is more prominent in Hodgkin lymphoma than DLBCL","volume":"131","author":"Vari","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100832_bb0015","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1200\/JCO.19.01492","article-title":"Nivolumab combined with brentuximab vedotin for relapsed\/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase II checkmate 436 study","volume":"37","author":"Zinzani","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2021.100832_bb0020","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.blre.2012.12.002","article-title":"Extracellular vesicles in physiological and pathological conditions","volume":"27","author":"Yuana","year":"2013","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2021.100832_bb0025","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.blre.2016.04.002","article-title":"Myeloid-derived suppressor cells: the green light for myeloma immune escape","volume":"30","author":"Malek","year":"2016","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2021.100832_bb0030","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1126\/science.aae0491","article-title":"The epigenetic landscape of T cell exhaustion","volume":"354","author":"Sen","year":"2016","journal-title":"Science."},{"key":"10.1016\/j.blre.2021.100832_bb0035","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2021.100832_bb0040","doi-asserted-by":"crossref","first-page":"20683","DOI":"10.1074\/jbc.M117.809053","article-title":"MicroRNA-155 induction via TNF-\u03b1 and IFN-\u03b3 suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells","volume":"292","author":"Yee","year":"2017","journal-title":"J Biol Chem"},{"key":"10.1016\/j.blre.2021.100832_bb0045","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.blre.2015.11.003","article-title":"Immune checkpoint blockade: releasing the brake towards hematological malignancies","volume":"30","author":"Xia","year":"2016","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2021.100832_bb0050","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"key":"10.1016\/j.blre.2021.100832_bb0055","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2021.100832_bb0060","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T cells during chronic viral infection","volume":"439","author":"Barber","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.blre.2021.100832_bb0065","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.immuni.2016.01.018","article-title":"Glycogen synthase kinase 3 inactivation drives T-bet-mediated downregulation of co-receptor PD-1 to enhance CD8(+) Cytolytic T cell responses","volume":"44","author":"Taylor","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.blre.2021.100832_bb0070","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.immuni.2011.06.015","article-title":"Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells","volume":"35","author":"Youngblood","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.blre.2021.100832_bb0075","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"key":"10.1016\/j.blre.2021.100832_bb0080","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1600-065X.2009.00767.x","article-title":"PD-1 signaling in primary T cells","volume":"229","author":"Riley","year":"2009","journal-title":"Immunol Rev"},{"key":"10.1016\/j.blre.2021.100832_bb0085","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","article-title":"CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms","volume":"25","author":"Parry","year":"2005","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.blre.2021.100832_bb0090","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1084\/jem.20112741","article-title":"Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2","volume":"209","author":"Yokosuka","year":"2012","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2021.100832_bb0095","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1126\/science.aaf1292","article-title":"T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.blre.2021.100832_bb0100","doi-asserted-by":"crossref","first-page":"ra46","DOI":"10.1126\/scisignal.2002796","article-title":"Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation","volume":"5","author":"Patsoukis","year":"2012","journal-title":"Sci Signal"},{"key":"10.1016\/j.blre.2021.100832_bb0105","doi-asserted-by":"crossref","first-page":"6692","DOI":"10.1038\/ncomms7692","article-title":"PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation","volume":"6","author":"Patsoukis","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2021.100832_bb0110","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood-2014-11-610436","article-title":"Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells","volume":"125","author":"Reichel","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100832_bb0115","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2326-6066.CIR-16-0201","article-title":"Classical Hodgkin lymphoma with reduced \u03b22M\/MHC class I expression is associated with inferior outcome independent of 9p24.1 status","volume":"4","author":"Roemer","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.blre.2021.100832_bb0120","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ccr.2011.11.006","article-title":"Combined genetic inactivation of \u03b22-microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma","volume":"20","author":"Challa-Malladi","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2021.100832_bb0125","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1172\/JCI137051","article-title":"Programmed cell death protein 1 on natural killer cells: fact or fiction?","volume":"130","author":"Cho","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2021.100832_bb0130","doi-asserted-by":"crossref","first-page":"1557030","DOI":"10.1080\/2162402X.2018.1557030","article-title":"PD-1 in human NK cells: evidence of cytoplasmic mRNA and protein expression","volume":"8","author":"Mariotti","year":"2019","journal-title":"Oncoimmunology."},{"key":"10.1016\/j.blre.2021.100832_bb0135","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1038\/s41591-020-1006-1","article-title":"A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma","volume":"26","author":"Cader","year":"2020","journal-title":"Nat Med"},{"issue":"25","key":"10.1016\/j.blre.2021.100832_bb0140","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1182\/blood.2020008553","article-title":"Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1","volume":"136","author":"Reinke","year":"2020","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100832_bb0145","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood.2019004701","article-title":"A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"136","author":"Bartlett","year":"2020","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100832_bb0150","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.blre.2021.100832_bb0155","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1085146","article-title":"PD-1 expression on dendritic cells suppresses CD8(+) T cell function and antitumor immunity","volume":"5","author":"Lim","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.blre.2021.100832_bb0160","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1084\/jem.20130790","article-title":"RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance","volume":"211","author":"Xiao","year":"2014","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2021.100832_bb0165","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.4049\/jimmunol.1003496","article-title":"The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo","volume":"187","author":"Paterson","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2021.100832_bb0170","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1182\/blood-2010-01-265975","article-title":"B7-H1\/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance","volume":"116","author":"Park","year":"2010","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100832_bb0175","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat Immunol"},{"key":"10.1016\/j.blre.2021.100832_bb0180","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1182\/blood.2019000889","article-title":"EBV microRNA-BHRF1-2-5p targets the 3\u2019UTR of immune checkpoint ligands PD-L1 and PD-L2","volume":"134","author":"Cristino","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100832_bb0185","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1084\/jem.20160801","article-title":"PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity","volume":"214","author":"Juneja","year":"2017","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2021.100832_bb0190","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1182\/blood-2017-03-770719","article-title":"Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma","volume":"130","author":"Carey","year":"2017","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100832_bb0195","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/jclinpath-2017-204853","article-title":"PD-L1","volume":"71","author":"Kythreotou","year":"2018","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.blre.2021.100832_bb0200","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1182\/blood-2007-05-085159","article-title":"PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma","volume":"111","author":"Yamamoto","year":"2008","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100832_bb0205","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell."},{"key":"10.1016\/j.blre.2021.100832_bb0210","doi-asserted-by":"crossref","first-page":"R48","DOI":"10.1186\/bcr2605","article-title":"Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule","volume":"12","author":"Ghebeh","year":"2010","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.blre.2021.100832_bb0215","doi-asserted-by":"crossref","first-page":"28910","DOI":"10.1038\/srep28910","article-title":"Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients","volume":"6","author":"Satelli","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.blre.2021.100832_bb0220","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/s41556-020-0575-z","article-title":"PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis","volume":"22","author":"Hou","year":"2020","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.blre.2021.100832_bb0225","doi-asserted-by":"crossref","first-page":"36722","DOI":"10.1038\/srep36722","article-title":"B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8(+) T cells","volume":"6","author":"Liu","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.blre.2021.100832_bb0230","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41590-020-0620-x","article-title":"PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer","volume":"21","author":"Diskin","year":"2020","journal-title":"Nat Immunol"},{"key":"10.1016\/j.blre.2021.100832_bb0235","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/s43018-020-0075-x","article-title":"PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer","volume":"1","author":"Oh","year":"2020","journal-title":"Nat Cancer"},{"key":"10.1016\/j.blre.2021.100832_bb0240","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1158\/2159-8290.CD-18-1259","article-title":"The mechanism of anti-PD-L1 antibody efficacy against PD-L1-negative tumors identifies NK cells expressing PD-L1 as a cytolytic effector","volume":"9","author":"Dong","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.blre.2021.100832_bb0245","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.immuni.2016.07.017","article-title":"Programmed death-1 ligand 2-mediated regulation of the PD-L1 to PD-1 Axis is essential for establishing CD4(+) T cell immunity","volume":"45","author":"Karunarathne","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.blre.2021.100832_bb0250","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1038\/s41467-020-18570-x","article-title":"PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade","volume":"11","author":"Peng","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2021.100832_bb0255","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100832_bb0260","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2013-10-535443","article-title":"Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma","volume":"123","author":"Twa","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100832_bb0265","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1097\/PAS.0000000000000297","article-title":"Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain","volume":"38","author":"Shi","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.blre.2021.100832_bb0270","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2021.100832_bb0275","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nature09754","article-title":"MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers","volume":"471","author":"Steidl","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.blre.2021.100832_bb0280","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","article-title":"Targetable genetic features of primary testicular and primary central nervous system lymphomas","volume":"127","author":"Chapuy","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100832_bb0285","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1182\/blood-2015-11-683003","article-title":"Comprehensive characterization of programmed death ligand structural rearrangements in B-cell non-Hodgkin lymphomas","volume":"128","author":"Chong","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100832_bb0290","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/modpathol.2011.116","article-title":"Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations","volume":"24","author":"Eberle","year":"2011","journal-title":"Mod Pathol"},{"key":"10.1016\/j.blre.2021.100832_bb0295","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.blre.2015.06.002","article-title":"Deregulated JAK\/STAT signalling in lymphomagenesis, and its implications for the development of new targeted therapies","volume":"29","author":"Scott","year":"2015","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2021.100832_bb0300","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2021.100832_bb0305","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1365-2141.2004.04902.x","article-title":"Epstein-Barr virus-associated Hodgkin\u2019s lymphoma","volume":"125","author":"Gandhi","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100832_bb0310","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/his.13857","article-title":"Clinicopathological evaluation of the programmed cell death 1 (PD1)\/programmed cell death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcome","volume":"75","author":"Veloza","year":"2019","journal-title":"Histopathology"},{"key":"10.1016\/j.blre.2021.100832_bb0315","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1182\/blood-2018-10-879015","article-title":"PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype","volume":"133","author":"Godfrey","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100832_bb0320","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1182\/blood-2015-12-686550","article-title":"Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas","volume":"127","author":"Georgiou","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100832_bb0325","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature18294","article-title":"Aberrant PD-L1 expression through 3\u2019-UTR disruption in multiple cancers","volume":"534","author":"Kataoka","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.blre.2021.100832_bb0330","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/cei.12716","article-title":"The impact of HLA class I and EBV latency-II antigen-specific CD8(+) T cells on the pathogenesis of EBV(+) Hodgkin lymphoma","volume":"183","author":"Jones","year":"2016","journal-title":"Clin Exp Immunol"},{"issue":"11","key":"10.1016\/j.blre.2021.100832_bb0335","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1182\/blood.2020007245","article-title":"Frequent genetic alterations in immune checkpoint-related genes in intravascular large B-cell lymphoma","volume":"137","author":"Shimada","year":"2020","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2021.100832_bb0340","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1182\/blood.2020008520","article-title":"EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity","volume":"137","author":"Gandhi","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100832_bb0345","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1038\/s41375-019-0380-5","article-title":"Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas","volume":"33","author":"Kataoka","year":"2019","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2021.100832_bb0350","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/ajh.22252","article-title":"Tumor-specific but not nonspecific cell-free circulating DNA can be used to monitor disease response in lymphoma","volume":"87","author":"Jones","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2021.100832_bb0355","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3324\/haematol.2016.154039","article-title":"Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14","volume":"102","author":"Hertzberg","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2021.100832_bb0360","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12040877","article-title":"Prognostic impact of tumor-associated macrophages on survival is checkpoint dependent in classical hodgkin lymphoma","volume":"12","author":"Karihtala","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.blre.2021.100832_bb0365","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1016\/S2352-3026(15)00150-7","article-title":"Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study","volume":"2","author":"Keane","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2021.100832_bb0370","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1038\/leu.2014.137","article-title":"High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-cell lymphoma: results from a French multicenter clinical trial","volume":"28","author":"Rossille","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2021.100832_bb0375","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood-2015-02-629600","article-title":"Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma","volume":"126","author":"Kiyasu","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100832_bb0380","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/bloodadvances.2019001390","article-title":"LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma","volume":"4","author":"Keane","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2021.100832_bb0385","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1158\/1078-0432.CCR-16-1576","article-title":"The T-cell receptor repertoire influences the tumor microenvironment and is associated with survival in aggressive B-cell lymphoma","volume":"23","author":"Keane","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2021.100832_bb0390","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/ejh.13274","article-title":"The tumour microenvironment is immuno-tolerogenic and a principal determinant of patient outcome in EBV-positive diffuse large B-cell lymphoma","volume":"103","author":"Keane","year":"2019","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2021.100832_bb0395","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2015-02-630632","article-title":"EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment","volume":"126","author":"Nicolae","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100832_bb0400","doi-asserted-by":"crossref","first-page":"105999","DOI":"10.1016\/j.intimp.2019.105999","article-title":"Prognostic and clinicopathological significance of PD-1\/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma","volume":"77","author":"Xie","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.blre.2021.100832_bb0405","doi-asserted-by":"crossref","first-page":"18933","DOI":"10.18632\/oncotarget.3662","article-title":"microRNA-4717 differentially interacts with its polymorphic target in the PD1 3\u2032 untranslated region: a mechanism for regulating PD-1 expression and function in HBV-associated liver diseases","volume":"6","author":"Zhang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.blre.2021.100832_bb0410","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/bjh.14201","article-title":"The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era","volume":"175","author":"Blaker","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100832_bb0415","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1200\/JCO.18.02365","article-title":"Progression of disease within 24 months in follicular lymphoma is associated with reduced Intratumoral immune infiltration","volume":"37","author":"Tobin","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2021.100832_bb0420","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1235107","article-title":"PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: correlation with tumor-infiltrating immune cells and clinical outcome","volume":"5","author":"Obeid","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.blre.2021.100832_bb0425","doi-asserted-by":"crossref","first-page":"E7769","DOI":"10.1073\/pnas.1607836113","article-title":"Association of PD-1\/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors","volume":"113","author":"Danilova","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2021.100832_bb0430","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1158\/2159-8290.CD-15-0563","article-title":"Adaptive immune resistance: how Cancer protects from immune attack","volume":"5","author":"Ribas","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.blre.2021.100832_bb0435","unstructured":"Nath K, Law SC, Sabdia MB, Gunawardana J, de Long LM, Sester D, et al. Intratumoral T-cells have a differential impact on FDG-PET parameters in follicular lymphoma. Blood Adv [In press]."},{"key":"10.1016\/j.blre.2021.100832_bb0440","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2021.100832_bb0445","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1200\/JCO.19.01389","article-title":"Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma","volume":"37","author":"Armand","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2021.100832_bb0450","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.18.00766","article-title":"Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study","volume":"37","author":"Ansell","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2021.100832_bb0455","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2021.100832_bb0460","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2021.100832_bb0465","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2021.100832_bb0470","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.2019000324","article-title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100832_bb0475","doi-asserted-by":"crossref","first-page":"8005","DOI":"10.1200\/JCO.2020.38.15_suppl.8005","article-title":"KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R\/R cHL)","volume":"38","author":"Kuruvilla","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2021.100832_bb0480","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood-2019-122576","article-title":"Brentuximab vedotin and nivolumab for relapsed or refractory classic hodgkin lymphoma: long-term follow-up results from the single-arm phase 1\/2 study","volume":"134","author":"Moskowitz","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100832_bb0485","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00066-016-1050-4","article-title":"Checkpoint inhibitors and radiation treatment in Hodgkin\u2019s lymphoma\u202f: new study concepts of the German Hodgkin Study Group","volume":"193","author":"Baues","year":"2017","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.blre.2021.100832_bb0490","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1159\/000481800","article-title":"Checkpoint inhibition in Hodgkin lymphoma - a review","volume":"40","author":"Br\u00f6ckelmann","year":"2017","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.blre.2021.100832_bb0495","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/bjh.15778","article-title":"Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions","volume":"185","author":"Lees","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100832_bb0500","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1182\/blood-2017-01-764209","article-title":"PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma","volume":"129","author":"Nayak","year":"2017","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100832_bb0505","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMc1704767","article-title":"PD-1 blockade in mediastinal gray-zone lymphoma","volume":"377","author":"Melani","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2021.100832_bb0510","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100832_bb0515","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/S2352-3026(18)30217-5","article-title":"Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1\/2a study","volume":"6","author":"Younes","year":"2019","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1016\/j.blre.2021.100832_bb0520","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1182\/blood.2019004753","article-title":"Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed\/refractory follicular lymphoma","volume":"137","author":"Armand","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100832_bb0525","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1470-2045(13)70551-5","article-title":"Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial","volume":"15","author":"Westin","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2021.100832_bb0530","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/hon.2437_108","article-title":"High response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: interim results of an on open-label, phase II study","volume":"35","author":"Nastoupil","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.blre.2021.100832_bb0535","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2020-136024","article-title":"Safety and efficacy of induction and maintenance avelumab plus R-CHOP in patients with diffuse large B-cell lymphoma (DLBCL): analysis of the phase II Avr-CHOP study","volume":"136","author":"Hawkes","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100832_bb0540","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2021.100832_bb0545","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s43018-019-0003-0","article-title":"PAK4 inhibition improves PD-1 blockade immunotherapy","volume":"1","author":"Abril-Rodriguez","year":"2019","journal-title":"Nat Cancer"},{"key":"10.1016\/j.blre.2021.100832_bb0550","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1200\/JCO.2016.71.9476","article-title":"Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH)","volume":"35","author":"Peters","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2021.100832_bb0555","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","article-title":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial","volume":"17","author":"Kaufman","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2021.100832_bb0560","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.2016.67.9761","article-title":"Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer","volume":"34","author":"Massard","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2021.100832_bb0565","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1182\/blood.V128.22.2999.2999","article-title":"PD-1 blockade after epigenetic therapy in patients with relapsed or refractory hodgkin lymphoma: higher-than-expected rate of complete responses","volume":"128","author":"Falchi","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100832_bb0570","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1200\/JCO.18.02151","article-title":"Addition of low-dose decitabine to anti-PD-1 antibody camrelizumab in relapsed\/refractory classical hodgkin lymphoma","volume":"37","author":"Nie","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2021.100832_bb0575","series-title":"A safety and pharmacology study of atezolizumab (MPDL3280A) administered with obinutuzumab or tazemetostat in participants with relapsed\/refractory follicular lymphoma and diffuse large B-cell lymphoma","author":"Clinical Trials","year":"2014"},{"key":"10.1016\/j.blre.2021.100832_bb0580","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.blre.2021.100832_bb0585","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1158\/2159-8290.CD-16-0975","article-title":"CREBBP inactivation promotes the development of HDAC3-dependent lymphomas","volume":"7","author":"Jiang","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.blre.2021.100832_bb0590","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.blre.2021.100832_bb0595","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2021.100832_bb0600","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1182\/blood.2020007878","article-title":"Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy","volume":"137","author":"Moik","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100832_bb0605","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1182\/blood-2016-09-738385","article-title":"Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma","volume":"129","author":"Merryman","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100832_bb0610","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s12882-018-1003-5","article-title":"PD 1 checkpoint inhibition in solid organ transplants: 2 sides of a coin - case report","volume":"19","author":"Goldman","year":"2018","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.blre.2021.100832_bb0615","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejca.2018.09.017","article-title":"Anti-PD-1\/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B\/C infection","volume":"104","author":"Tio","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.blre.2021.100832_bb0620","doi-asserted-by":"crossref","first-page":"614876","DOI":"10.3389\/fonc.2020.614876","article-title":"PD-1 blockade aggravates Epstein-Barr virus(+) post-transplant lymphoproliferative disorder in humanized mice resulting in central nervous system involvement and CD4(+) T cell dysregulations","volume":"10","author":"Volk","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2021.100832_bb0625","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","article-title":"Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1\/PD-L1","volume":"23","author":"Champiat","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2021.100832_bb0630","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1182\/blood.2019002038","article-title":"Rapid progression of adult T-cell leukemia\/lymphoma as tumor-infiltrating Tregs after PD-1 blockade","volume":"134","author":"Rauch","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100832_bb0635","doi-asserted-by":"crossref","first-page":"9999","DOI":"10.1073\/pnas.1822001116","article-title":"PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer","volume":"116","author":"Kamada","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2021.100832_bb0640","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1016\/j.str.2015.09.010","article-title":"Structure of the complex of human programmed death 1, PD-1, and its ligand PD-L1","volume":"23","author":"Zak","year":"2015","journal-title":"Structure"},{"key":"10.1016\/j.blre.2021.100832_bb0645","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.drudis.2016.04.011","article-title":"From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1\/PD-L1 pathway","volume":"21","author":"Zhan","year":"2016","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.blre.2021.100832_bb0650","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41401-020-0366-x","article-title":"Small molecule inhibitors targeting the PD-1\/PD-L1 signaling pathway","volume":"42","author":"Wu","year":"2021","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.blre.2021.100832_bb0655","doi-asserted-by":"crossref","first-page":"4689","DOI":"10.1242\/jcs.00838","article-title":"The small RNA world","volume":"116","author":"Finnegan","year":"2003","journal-title":"J Cell Sci"},{"key":"10.1016\/j.blre.2021.100832_bb0660","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/bjc.2015.253","article-title":"MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients","volume":"113","author":"Pichler","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.blre.2021.100832_bb0665","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.biopha.2017.11.146","article-title":"Overexpressed miR-195 attenuated immune escape of diffuse large B-cell lymphoma by targeting PD-L1","volume":"98","author":"He","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.blre.2021.100832_bb0670","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12943-019-0977-3","article-title":"MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1\/PD-L1-mediated lymphoma cell interaction with CD8+T cells","volume":"18","author":"Zheng","year":"2019","journal-title":"Mol Cancer"},{"key":"10.1016\/j.blre.2021.100832_bb0675","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s11658-019-0190-9","article-title":"MiR-214 prevents the progression of diffuse large B-cell lymphoma by targeting PD-L1","volume":"24","author":"Sun","year":"2019","journal-title":"Cell Mol Biol Lett"},{"key":"10.1016\/j.blre.2021.100832_bb0680","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00262-020-02507-w","article-title":"miRNA-5119 regulates immune checkpoints in dendritic cells to enhance breast cancer immunotherapy","volume":"69","author":"Zhang","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.blre.2021.100832_bb0685","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd.2016.246","article-title":"MicroRNA therapeutics: towards a new era for the management of cancer and other diseases","volume":"16","author":"Rupaimoole","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.blre.2021.100832_bb0690","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/s41467-017-01883-9","article-title":"DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells","volume":"8","author":"Sato","year":"2017","journal-title":"Nat Commun"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X21000382?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X21000382?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:27:04Z","timestamp":1759436824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X21000382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":138,"alternative-id":["S0268960X21000382"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2021.100832","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunity reloaded: Deconstruction of the PD-1 axis in B cell lymphomas","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2021.100832","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100832"}}